DABIGATRAN
DABIGATRAN ETEXILATE
- Strength
- 75 mg/1
- Form
- Capsule
- Class
- Direct Thrombin Inhibitor
Novadoz Pharmaceuticals LLC
Listed by Major Pharmaceuticals
| Dosage form | Capsule, Coated Pellets |
|---|---|
| Route | Oral |
| Drug class | Direct Thrombin Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 0904-7254 |
| FDA application | ANDA208040 |
| RxNorm concept | 1037045 |
| Package sizes listed | 1 |
| Marketed since | June 2025 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
DABIGATRAN ETEXILATE
Novadoz Pharmaceuticals LLC
DABIGATRAN ETEXILATE
AvKARE
DABIGATRAN ETEXILATE
American Health Packaging
DABIGATRAN ETEXILATE
A-S Medication Solutions
DABIGATRAN ETEXILATE
AvPAK
DABIGATRAN ETEXILATE
AvKARE
DABIGATRAN ETEXILATE
A-S Medication Solutions
DABIGATRAN ETEXILATE
American Health Packaging
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.